Publications by authors named "Mufeed Raoof"
To study the impact of depression and anxiety on health-related quality of life (HRQOL) in patients with multiple sclerosis (pwMS) in the UAE. All consecutive patients attending the MS clinic over a fourmonth period, October 2014 through February 2015, at Sheikh Khalifa Medical city (SKMC) were asked to complete The World Health Organization quality of life abbreviated scale (WHOQOL-BREF), the Patient Health Questionnaire nine-item (PHQ-9) depression scale, and Generalized Anxiety Disorder seven-item (GAD-7) scale. These last two scales were used to screen for depression and anxiety disorders respectively.
View Article and Find Full Text PDFPurpose: to investigate potential factors impacting HRQOL among PWE at a medical facility in the UAE.
Methods: Depression, anxiety, and health-related quality of life were assessed in 160 adult patients with epilepsy from September 2014 to January 2015 at Sheikh Khalifa Medical City (SKMC). The World Health Organization Quality of Life abbreviated scale (WHOQOL-BREF), the Patient Health Questionnaire nine-item (PHQ-9) depression scale, and Generalized Anxiety Disorder seven-item (GAD-7) scale were administered.
Depression and anxiety are highly prevalent in patients with epilepsy (PWE), with prevalence rates ranging from 20% to 55%. The cause of this increased rate is multifactorial. Depression and epilepsy are thought to share the same pathogenic mechanism.
View Article and Find Full Text PDFArticle Synopsis
- Depression and anxiety affect a significant number of patients with epilepsy (20% to 55%), but their prevalence in the Middle East, especially the UAE, has been largely unexamined.
- A study involving 186 epilepsy patients revealed that nearly one-third showed signs of depression and anxiety, which was notably higher than in matched control groups.
- Despite high levels of these mental health issues, around 66% of patients with depression and anxiety were not receiving appropriate treatment, such as antidepressants or anti-anxiety medications.
Depression and anxiety are reported to be prevalent in patients with MS, with prevalence rates ranging from 20% to 50%. Unfortunately, the rates, patterns, and risk factors are not well studied in our Middle East region, and, to our knowledge, not at all in UAE. Using standardized screening tools, we observed that 17% and 20% of 80 patients seen in MS clinic had scores consistent with major depression and anxiety disorders, respectively, at a rate that was not statistically different when compared to age and sex matched controls.
View Article and Find Full Text PDF